Autologous interleukin-15-armored anti-glypican-3 CAR-iC9-expressing T lymphocytes
Term · Oncology and biomedicine · MLC-T-ONC-011672
A preparation of T lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) specific for glypican-3 (GPC3) and express interleukin-15 (IL-15) and the suicide gene, inducible caspase 9 (iCasp9 or iC9), with potential immunostimulating and antineoplastic activities. Upon administration, autologous IL-15-armored anti-GPC3 CAR-iC9-expressing T lymphocytes specifically target and bind to GPC3-expressing tumor cells, resulting in tumor cell lysis. GPC3, a heparan sulfate proteoglycan and a member of the glypican family, is overexpressed on certain tumor cell types while minimally expressed on normal, healthy cells; GPC3 plays an important role in cellular proliferation and differentiation. IL-15 is a pro-survival cytokine that potentiates, in addition to promoting T-cell proliferation and persistence, the immune response against tumor cells. The iCasp9 safety switch consists of a full-length caspase 9, including its caspase recruitment domain, linked to a human FK506 drug-binding domain with an F36V mutation (FKBP12-F36V). If the administered CAR T cells lead to unacceptable side effects, the chemical homodimerizer AP1903 can be administered. AP1903 binds to the FKBP12-F36V drug-binding domain, activates caspase 9 and results in apoptosis of the administered CAR T cells.
| Identifier | MLC-T-ONC-011672 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | interleukin-15 armored glypican 3-specific CAR iCasp9-expressing autologous T cells; autologous anti-GPC3 CAR-IL-15-iCasp9-expressing T lymphocytes; autologous GPC3-CAR-IL-15-iC9-expressing T cells; autologous iC9-expressing CATCH T cells; autologous GPC3-specific CAR-IL-15-iCasp9 T cells; autologous interleukin-15-armored anti-GPC3 CAR-iC9-expressing T lymphocytes |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-011672",
"term": "Autologous interleukin-15-armored anti-glypican-3 CAR-iC9-expressing T lymphocytes",
"field": "Oncology and biomedicine",
"definition": "A preparation of T lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) specific for glypican-3 (GPC3) and express interleukin-15 (IL-15) and the suicide gene, inducible caspase 9 (iCasp9 or iC9), with potential immunostimulating and antineoplastic activities. Upon administration, autologous IL-15-armored anti-GPC3 CAR-iC9-expressing T lymphocytes specifically target and bind to GPC3-expressing tumor cells, resulting in tumor cell lysis. GPC3, a heparan sulfate proteoglycan and a member of the glypican family, is overexpressed on certain tumor cell types while minimally expressed on normal, healthy cells; GPC3 plays an important role in cellular proliferation and differentiation. IL-15 is a pro-survival cytokine that potentiates, in addition to promoting T-cell proliferation and persistence, the immune response against tumor cells. The iCasp9 safety switch consists of a full-length caspase 9, including its caspase recruitment domain, linked to a human FK506 drug-binding domain with an F36V mutation (FKBP12-F36V). If the administered CAR T cells lead to unacceptable side effects, the chemical homodimerizer AP1903 can be administered. AP1903 binds to the FKBP12-F36V drug-binding domain, activates caspase 9 and results in apoptosis of the administered CAR T cells.",
"synonyms": [
"interleukin-15 armored glypican 3-specific CAR iCasp9-expressing autologous T cells",
"autologous anti-GPC3 CAR-IL-15-iCasp9-expressing T lymphocytes",
"autologous GPC3-CAR-IL-15-iC9-expressing T cells",
"autologous iC9-expressing CATCH T cells",
"autologous GPC3-specific CAR-IL-15-iCasp9 T cells",
"autologous interleukin-15-armored anti-GPC3 CAR-iC9-expressing T lymphocytes"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/autologous-interleukin-15-armored-anti-glypican-3-car-ic9-expressing-t/"
}
Record 3,007 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.